|
Kenneth Taylor is the Chief Executive Officer of Antipodean Pharmaceuticals. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Baltimore, Maryland and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical research in Princeton, New Jersey. In 1975 he joined Roche to establish a pharmacology research and clinical pharmacology program in Sydney, Australia and later was appointed Medical Director then Managing Director for Roche in New Zealand. In 1990, he was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to Roche Bioscience, a research center. He later returned to New Zealand to manage the Roche affiliate and also to help Roche find research alliances in the Asia Pacific area. Dr Taylor is an Adjunct Professor of Pharmacy at the University of Otago, Dunedin, New Zealand and was a director of the Foundation for Research, Science and Technology, the New Zealand government's agency for funding scientific research. Born and educated in New Zealand, Dr Taylor earned honors and doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine. Additionally, in 1986, he completed a business management program at IMD in Lausanne, Switzerland. |
|
|
Michelle Lockhart - Project Management |
|
Ms Lockhart has 10 years regulatory, marketing and clinical experience with Roche in both New Zealand and the UK. She also has six years project management experience with The Medicines Company. Michelle is responsible for regulatory and clinical programs. She has a Pharmacy degree and a Masters in management. |
|
|
